Drug intelligence / Profile preview

NKTR-0169

Development stage: Preclinical
Lead developer: Nektar Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NKTR-0169 (also known as BD1) is a computationally designed monoclonal antibody targeting Tumor Necrosis Factor alpha (TNFα), developed by Biolojic Design in partnership with Nektar Therapeutics. Engineered using Biolojic's proprietary AI-based platform, the antibody is designed to provide precise modulation of TNFα-driven inflammatory pathways. This mechanism is intended to treat various autoimmune and inflammatory diseases by neutralizing the pro-inflammatory effects of TNFα. The program is currently in the IND-enabling phase of development.

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on NKTR-0169.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NKTR-0169.

Explore the full profile